TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis-Reference-Cited by-同舟云学术

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Published:2018-02 Issue:7693 Volume:554 Page:538-543
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Tauriello Daniele V. F.,Palomo-Ponce Sergio,Stork Diana,Berenguer-Llergo Antonio,Badia-Ramentol Jordi,Iglesias Mar,Sevillano Marta,Ibiza Sales,Cañellas Adrià,Hernando-Momblona Xavier,Byrom Daniel,Matarin Joan A.,Calon Alexandre,Rivas Elisa I.,Nebreda Angel R.,Riera Antoni,Attolini Camille Stephan-Otto,Batlle Eduard

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature25492.pdf

Reference43 articles.

1. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283–4288 (2008)

2. Mlecnik, B. et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl. Med. 8, 327ra26 (2016)

3. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006)

4. Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320–329 (2015)

5. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012)

Cited by 1352 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intestinal organ chips for disease modelling and personalized medicine;Nature Reviews Gastroenterology & Hepatology;2024-08-27

2. Loss of ARID3A perturbs intestinal epithelial proliferation–differentiation ratio and regeneration;Journal of Experimental Medicine;2024-08-16

3. Molecular mechanisms driving the interactions between platelet and gastric cancer cells during peritoneal dissemination;Oncology Letters;2024-08-13

4. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

5. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08